Remarkably, the elevated plasma levels of NET-associated proteins, such as NE, MPO and DNA-MPO complexes in MS patients, correlate with clinical disability and lesion burden (24, 25, 62). This evidence concerns the gene ELANE and myeloid sarcoma.